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Abstract
Background: The connection of the variable part of the heavy chain (VH) and and the variable
part of the light chain (VL) by a peptide linker to form a consecutive polypeptide chain (single chain
antibody, scFv) was a breakthrough for the functional production of antibody fragments in
Escherichia coli. Being double the size of fragment variable (Fv) fragments and requiring assembly of
two independent polypeptide chains, functional Fab fragments are usually produced with
significantly lower yields in E. coli. An antibody design combining stability and assay compatibility of
the fragment antigen binding (Fab) with high level bacterial expression of single chain Fv fragments
would be desirable. The desired antibody fragment should be both suitable for expression as
soluble antibody in E. coli and antibody phage display.
Results: Here, we demonstrate that the introduction of a polypeptide linker between the fragment
difficult (Fd) and the light chain (LC), resulting in the formation of a single chain Fab fragment
(scFab), can lead to improved production of functional molecules. We tested the impact of various
linker designs and modifications of the constant regions on both phage display efficiency and the
yield of soluble antibody fragments. A scFab variant without cysteins (scFabΔC) connecting the
constant part 1 of the heavy chain (CH1) and the constant part of the light chain (CL) were best
suited for phage display and production of soluble antibody fragments. Beside the expression
system E. coli, the new antibody format was also expressed in Pichia pastoris. Monovalent and
divalent fragments (DiFabodies) as well as multimers were characterised.
Conclusion: A new antibody design offers the generation of bivalent Fab derivates for antibody
phage display and production of soluble antibody fragments. This antibody format is of particular
value for high throughput proteome binder generation projects, due to the avidity effect and the
possible use of common standard sera for detection.
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Background
The production of functional antibody fragments in E. coli
was first described by Skerra and Plückthun [1]. Key to this
success was production in the periplasm, where the oxi-
dizing environment allows the formation of disulphide
bonds. Later, the linkage of the variable regions by a 15–
25 amino acid linker of both Fv chains improved the
expression of antibody fragments in E. coli [2,3]. However,
these so called single chain fragment variable (scFv) have
the tendency to form aggregates and are relatively unsta-
ble over longer periods of time [4]. Furthermore, some
scFvs show a reduced affinity of up to one order of magni-
tude compared to the corresponding Fab fragments [5].
Only in rare cases have scFvs with a higher affinity than
the associated Fab been found [6]. Because they are dou-
ble the molecular size, and require the production and
connection of two different polypeptides with a disul-
phide bond, folding and assembly of Fab fragments in the
periplasm of E. coli is less efficient than for scFvs [7]. A fur-
ther disadvantage of Fab fragments is the tendency of light
chains to form homo-dimers, which are known as Bence
Jones proteins [8,9]. Advantages of Fab fragments are their
high stability in long term storage [10] and their compat-
ibility with common detection antisera without the need
for a re-engineering step [11]. An antibody design com-
bining stability and assay compatibility of Fab fragments
with high level bacterial expression of single chain Fv frag-
ments would be desirable. The desired antibody fragment
should be both suitable for expression as soluble anti-
body in E. coli and antibody phage display.
Currently, most recombinant antibody fragments are gen-
erated by antibody phage display. Phage display technol-
ogy is based on the groundbreaking work of Smith [12].
Antibody phage display was first described by Huse et al.
[13] for the phage Lambda and by McCafferty et al. [14]
for the M13 phage. However, practical use was only
achieved by uncoupling antibody gene replication and
expression from the phage life cycle by locating them on
a separate plasmid (phagemid) to improve genetic stabil-
ity, handling, and screening of antibody libraries [15-18].
So far, naive scFv antibody libraries with a theoretical
diversity of up to 1011 independent clones [19] and Fab
antibody libraries with a size of 3.5 × 1010 clones [20]
have been generated as molecular repertoires for phage
display selections (overview given by Hust and Dübel
[21]). Antibody phage display is a key technology for the
generation of human recombinant antibody fragments
for therapy and diagnostics [22].
Here, we demonstrate, that the introduction of a polypep-
tide linker between Fd fragment and light chain, resulting
in the formation of a single chain Fab fragment (scFab),
can lead to improved production of antibody fragments.
We tested the impact of various linker lengths and the
presence of the disulphide bond on both the display effi-
ciency on phage and the yield of soluble antibody frag-
ment production in both prokaryotic and eukaryotic cells.
Results
Construction of the pHAL vectors with different antibody 
formats
The mouse anti hen egg white lysozyme antibody D1.3
[23,24] was reformated into a scFab with a 34 amino acid
linker, a scFab-2 with a 32 amino acid linker, a scFab+2
with a 36 amino acid linker and a scFab variant with a 34
amino acid linker where the cysteins connecting both
antibody chains were deleted (scFabΔC). Linker length
was chosen to cover the space between the LC carboxyter-
minus and the aminoterminal end of the Fd fragment, as
determined from X ray crystallographic data of Fab frag-
ments. To reduce the risk of adverse effects of the linker
sequence on the yield or folding, an intra-domain linker
sequence from the phage protein pIII was duplicated and
inserted. The antibody fragments were cloned into the
vector pHAL1 [9]. Vectors and linkers are given in figure 1.
Production of antibody phage
For evaluation of the antibody formats in phage display,
different pHAL1-D1.3 phagemids were packaged using
either Hyperphage or M13K07. As decribed, when using
the helperphage M13K07 (Fig. 2a) observed phage yields
were higher than when using Hyperphage (Fig. 2b). When
using M13K07, the yield was between 5 × 1012 and 1 ×
1013 phage per 30 mL culture, whereas 5 × 109 to 5 × 1010
phage per 30 mL culture were produced with Hyperphage.
The phage productions showed only marginal differences
between the antibody designs when using M13K07 or
Hyperphage.
SDS-PAGE analysis of antibody phage
D1.3 antibody phage preparations generated with
M13K07 or Hyperphage were separated by SDS-PAGE
under reducing conditions and blotted onto PVDF mem-
branes. pIII was visualised by immunostaining using a
monoclonal mouse anti-pIII antibody. pIII has a calcu-
lated molecular mass of 42,5 kDa, but it runs at an appar-
ent molecular mass of 65 kDa in SDS-PAGE [15,25]. As
expected, with phage produced using M13K07, the pIII
band at 65 kDa dominated, especially for Fab, reflecting a
low amount of fusion protein obtained in monovalent
display (Fig. 3a). The antibody-pIII fusion was more
prominent for the phage generated with Hyperphage and
is present in amounts almost equal to the unfused pIII
(Fig. 3b). The display efficiency of all scFabs variants was
better than that of the Fab fragments when using M13K07.
Antigen ELISA of antibody phage
Antigen binding of phage presenting the different anti-
body formats was determined by ELISA on lysozyme. 5 ×BMC Biotechnology 2007, 7:14 http://www.biomedcentral.com/1472-6750/7/14
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Vectors constructed for this study Figure 1
Vectors constructed for this study. A illustration of the different antibody formats, B the pHAL1-D1.3 vectors, C linker 
sequences of the scFab variants. Abbreviations: lacZ promoter: promoter of the bacterial lac operon; RBS: ribosome binding 
site; pelB: signal peptide sequence of bacterial pectate lyase, mediating secretion into the periplasmic space; VH: variable frag-
ment of the heavy chain; LC: light chain; ochre: ochre stop codon; amber: amber stop codon; strep-tag II: synthetic tag binding 
to streptactin. The elements of the inserts are not drawn to scale.
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108 phage/well were applied when M13K07 was used for
phage rescue, whereas 107 phage/well were used after
packaging with Hyperphage to compensate the known
differences in antibody presentation efficiency of both
systems [9,26,27].
In the case of phage packaged using M13K07 (Fig. 4a) the
scFv format showed best antigen binding. The Fab and
scFabΔC fragments bound the antigen approximately half
as good as the scFv. The presentation of functional anti-
body fragments on the phage surface was weaker for the
other scFab variants. The results for Hyperphage packaged
phage (Fig. 4b) were different. Here, the Fab and scFv frag-
ments were presented best as functional proteins on
phage, whereas the scFab variants were one third as good.
However, the scFabΔC was the best variant of the scFab
variants.
Production of soluble antibody variants using the phage 
display vector pHAL1
In order to investigate the production of soluble D1.3
scFab antibody fragments using phage display vectors, 20
μL aliquots of supernatant from an overnight expression
of E. coli strain XL1-Blue MRF', transformed with pHAL1-
D1.3 constructs in MTPs, were analyzed by antigen ELISAs
using mAb anti-strep tag for detection (Fig. 5a). This assay
rates the production and binding of the antibody frag-
ments in combination. The highest signals corresponding
to the best yield of functional antibody fragments were
obtained with the scFv and the scFabΔC variants, indicat-
ing that these formats were produced with a high fraction
of correctly folded antibody fragments. The deletion of
the cysteins in the scFab led to an increased yield of func-
tional antibody fragments. Additionally, the three anti-
body fragments were produced in 100 mL scale in E. coli
and purified using Protein L. Serial dilutions of equimolar
fractions, estimated by SDS-PAGE, of scFv, Fab and
scFabΔC were used to compare the content of functional
protein by lysozyme antigen ELISA (Fig. 5b). While same
amounts of scFv and scFabΔC bound the antigen almost
equal, the Fab fragments showed about 100× less antigen
binding.
Production of soluble antibody variants using the E. coli 
expression vector pOPE101-XP
Production of different D1.3 antibody fragments was also
tested using the dedicated E. coli expression vector
pOPE101-XP. 20 μL aliquots of the periplasmic fraction
and the osmotic shock fraction were analysed by separa-
tion on a reducing 10% SDS-PAGE and immunoblot. The
antibody fragments were detected using mAb mouse anti-
myc tag antibody. The estimated relative molecular mass
of all antibody fragments corresponded with the relative
molecular mass of the scFab and scFabΔC including all
tags of about 50.8 kDa, respectively 50.6 kDa, the scFv
with a relative molecular mass of about 26.7 kDa and the
Fd fragment of the Fab with a relative molecular mass of
about 24,7 kDa (Fig. 6).
Comparison of antibody phage titres (cfu) obtained from 30 mL of culture of six different D1.3 antibody fragment variants Figure 2
Comparison of antibody phage titres (cfu) obtained from 30 mL of culture of six different D1.3 antibody fragment variants. 
Packaged A with M13K07, B with Hyperphage. Mean value and standard deviations are from three completely independent 
experiments.
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Afterwards, the antibody fragments were purified by
IMAC followed by protein L affinity chromatography.
Purified samples of scFv, Fab, scFab and scFabΔC were
analyzed by surface plasmon resonance (SPR) to deter-
mine the affinity of the different antibody variants. Fol-
lowing affinities were measured: scFv: 1,04 × 10-8 M; Fab
1,91 × 10-8 M; scFab: 3,46 × 10-8 M; scFabΔC: 4,45 × 10-8
M. All measured affinities were in a similiar range, indicat-
ing that the newly introduced linker does not inhibit or
impair binding to the antigen.
Monomers and multimers of the antibody fragments were
separated by size exclusion chromatography. The gel fil-
tration results are shown exemplarily for the scFv (Fig. 7a)
and scFabΔC (Fig. 7b). The major peak corresponds to the
size calculated for the scFabΔC monomers, almost the
Immunoblot of antibody phage presenting different formats, produced with either M13K07 or Hyperphage Figure 3
Immunoblot of antibody phage presenting different formats, produced with either M13K07 or Hyperphage. A 1 × 1011 D1.3 
antibody phage produced with M13K07 were separated, B 3 × 108 D1.3 antibody phage produced with Hyperphage were sep-
arated. Phage were separated on a reducing 10 % SDS-PAGE, pIII was detected using mouse mAb anti-pIII.
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same amount represents dimers. The Fab existed as mon-
omer and the other scFabs also showed monomer, dimer
and multimer fractions (data not shown). The separated
monomers, dimers and multimer fraction of all different
antibody fragments were analysed by antigen binding
ELISA on lysozyme with 5 μM antibody fragments (Fig.
8a) and with a serial dilution of the antibody fragments
(Fig. 8b). The scFv was present as a dimer, and this anti-
body fragment showed the best binding to lysozyme.
Multimers of scFab and scFabΔC also showed good anti-
gen binding and the monomeric Fab, scFab and scFabΔC
fractions bound weaker to lysozyme. As expected, the
multimers bound better than the dimers and the dimers
bound better than the monomers to the antigen.
Production of scFab in P. pastoris
The D1.3scFabΔC was expressed in P. pastoris to investi-
gate compatability of the scFab format with an eukaryotic
expression system. Antibody fragments were purified by
protein L affinity chromatography and analysed by size
exclusion chromatography (Fig. 9). The scFabΔC showed
a strong tendency to form dimers. The gel filtration frac-
tion of monomeric, dimeric and presumably multimeric
scFabΔC were analysed by ELISA on lysozyme (Fig. 10). As
expected, due to the avidity effect, the multimers showed
strongest binding followed by dimers and monomers.
Discussion
So far, two antibody formats, Fabs and scFvs, have domi-
nated antibody phage display and the production of solu-
ble antibody fragments in E. coli. In this study, to test
whether it is possible to combine the advantages of both
formats, various single chain Fab (scFab) constructs were
generated and evaluated. In scFab, the light chain and the
Fd fragment of a Fab fragment are connected by a
polypeptide linker derived from the pIII of filamentous
phage M13. Three scFab variants with different linker
length from 32 to 36 amino acids and one 34 amino acid
variant with a deleted intermolecular disulphide bond
(scFabΔC) were compared to scFv and Fab using the lys-
ozyme binding antibody D1.3 [23,24] as a model anti-
body. In mammalian cells, an antibody construct using a
30 aa Gly-Ser linker to combine the HC fragment and the
LC has succesfully been produced to generate a single
chain IgG [28]. The scFab designs presented in this study,
in contrast, were evaluated both for their compatibility
with antibody phage display and production of soluble
antibody fragments in microbial production systems. For
the latter, in the prokaryotic expression system E. coli,
both the phage display phagemid pHAL1 [9] and the E.
coli expression vector pOPE101 [29] were tested. Addi-
tionally, the production in the eukaryotic expression sys-
tem using the yeast P. pastoris was demonstrated.
The applicability of the new antibody designs for anti-
body phage display is of major importance, as antibody
phage display is currently a major technology for the gen-
eration of human antibodies for research, diagnostic and
therapy (for reviews see [11,22,30]. Display of the differ-
ent antibody formats on phage was evaluated using the
Antigen binding phage ELISA of phage presenting D1.3 antibody fragment variants Figure 4
Antigen binding phage ELISA of phage presenting D1.3 antibody fragment variants. A 5 × 108 phage produced with M13K07, B 
107 phage produced with Hyperphage. Mean values and standard deviations of three completely independent experiments are 
given. The absorbance of scattered light at 620 nm was subtracted from the absorbance at 450 nm. The background signal of 
the antigen incubated with the detection antibody mAb anti-M13 HRP was subtracted. Antigen: 100 ng/well lysozyme. The 
D1.3 antibody phage were detected using mAb anti-M13 conjugated with HRP.
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two most frequently used helperphage, the standard
M13K07 and the pIII deficient Hyperphage [26,27,31],
which enforces polyvalent display on filamentous phage.
As described before, when the helperphage M13K07 was
used, phage yields were higher compared to Hyperphage.
This results from the lack of pIII when Hyperphage is
used, leaving the less well produced pIII fusion with the
antibody fragment as the sole source of this coat protein.
The fusion of pIII to different scFab variants did not signif-
icantly inhibit phage assembly with both helperphage,
indicating that all of the tested antibody designs are com-
patible with phage assembly. The length of the polypep-
Antigen binding ELISA of soluble antibody fragments produced in E. coli using pHAL1 with 1 μg/well lysozyme coated per well Figure 5
Antigen binding ELISA of soluble antibody fragments produced in E. coli using pHAL1 with 1 μg/well lysozyme coated per well. 
A 20 μL periplasmic fractions from production in MTPs of scFv, Fab and four scFab constructs were applied, the D1.3 antibod-
ies were detected using mouse mAb anti-Strep-Tag (1:10000), B serial dilutions of Protein L purified equimolar amounts of 
scFv, Fab and scFabΔC were applied, D1.3 antibody fragments were detected using Protein L conjugated to HRP (1:10000)
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Immunoblot of soluble antibody fragments produced using the E. coli expression vector pOPE101 Figure 6
Immunoblot of soluble antibody fragments produced using the E. coli expression vector pOPE101. 20 μL aliquots of E. coli peri-
plasmic fractions were separated on reducing 10% SDS-PAGE, pIII was detected using mouse mAb anti-myc tag and goat anti-
mouse IgG AP. Abbreviations: PE: periplasmic fraction; OS: osmotic shock preparation.
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tide linker used in the scFab variants had no influence on
phage packaging and antigen binding. In contrast, signifi-
cant benefit was achieved by removing the cysteins from
the carboxyterminus of Fd and LC, adding to the body of
evidence on the adverse effect of cysteins on the produc-
tion of proteins in E. coli [29].
The phage display vector pHAL1 can also be used for pro-
duction of soluble antibody fragments. This facilitates the
analysis of individual clones after the panning procedure,
because no recloning steps are necessary. Fractions of sol-
uble antibodies are analysed by ELISA on enzyme rating
the production and binding of the antibody fragments in
combination. Here, the scFv and scFabΔC designs showed
superior antigen binding compared to Fab and scFab.
Consistent to the results obtained from the antigen ELISA
using antibody phage, the length of the polypeptide linker
used in the scFab variants had no influence on the antigen
binding. Again, the cysteins connecting CH1 and CL
chains in Fab and scFabs had also a negative effect on the
production of functional antibody fragments. For further
analysis, the scFv, Fab, scFab with 34 amino acid linker
Size exclusion chromatography analysis of soluble antibody fragments produced using the E. coli expression vector pOPE101 Figure 7
Size exclusion chromatography analysis of soluble antibody fragments produced using the E. coli expression vector pOPE101. 
50 μg purified antibody fragments of the A scFv, or B scFabΔC format were separated on superdex 200. Calibration was done 
with Chymotrypsinogen (25 kDa), Ovalbumin (43 kDa), Albumin (67 kDa) and IgG (150 kDa).
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Antigen binding ELISA of soluble antibody fragments produced in E. coli using pOPE101 with 1 μg/well lysozyme coated per well Figure 8
Antigen binding ELISA of soluble antibody fragments produced in E. coli using pOPE101 with 1 μg/well lysozyme coated per 
well. A 5 μM gelfiltration purified fractions of scFv, Fab and four scFab constructs were applied per well, D1.3 antibody frag-
ments were detected using mAb anti-myc tag (1:25), the ELISA measurements were done in triplicate. B ELISA signals of serial 
dilutions of the different fractions of the antibody fragments.
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and the scFabΔC were produced in E. coli using the expres-
sion vector pOPE101 [29] and analysed in detail. The
measured affinities by surface plasmon resonance (SPR)
showed similiar results for all antibody variants and are in
contrast to the results of the functional ELISAs. The scFab
variants were found as monomers, dimers and multimers,
the scFv was only found as dimer, and the Fab occured
only as monomer. The multimeric and dimeric antibody
fragment fractions showed better antigen binding com-
pared to the monomeric states, indicating the expected
avidity benefit. The results obtained for E. coli could be
reproduced by analysis of scFabΔC produced in Pichia pas-
toris. This yeast expression system is of growing impor-
tance for antibody production because a glycosylation of
full size antibodies identical to that in humans was
achieved with glycoengineered P. pastoris lines [32].
In summary, the results show that scFab variants which
are fully compatible with antibody phage display and
superior to Fab fragments can be designed. Second, the
scFabs, in particular the delta cysteine variant (scFabΔC),
compensated for some of the disadvantages of soluble Fab
production in E. coli. However, in phage display, we see
the major advantage of the scFab format in the context of
an optimised procedure for the generation of large
amounts of binders on a proteome wide scale [30]. Here,
a streamlined process has to be developed and optimised
for significantly different parameters when compared to
the current "industry standard" methods applied to the
selection of therapeutic antibody candidates [11]. The
improved display and stability of a robust Fab-size frag-
ment that is compatible to widely used detection antisera
may be a significant advantage. Further, the dimerisation
offers an apparent affinity increase by avidity in most
assays, without it being necessary to re-engineer or sub-
clone the antibody's binding site. Otherwise the occur-
ance of different states in the scFab variants makes it
difficult the calculate the affinity. Furthermore, a mixture
of states can not be used for clinical purposes. The associ-
ation of two scFv polypeptide chains to form a noncova-
lent dimer (diabody) has been described frequently [33-
38]. We observed a similar capability of the scFab
polypeptides, resulting in a protein fraction with double
the molecular mass and increased binding due to the avid-
ity provided by two binding sites. This molecular species
was shown to be formed independently from the produc-
tion host and its chaperone equipment, in both the gram-
negative bacterium E. coli and the yeast Pichia pastoris. Fur-
ther, even TriFabodies, TetraFabodies and larger assem-
blies of the same polypeptide chain seem to be formed in
analogy to the Triabodies and Tetrabodies described for
the scFv constructs (Fig. 11) [38]. TetraFabodies may be
favoured among these multimers for topological reasons.
The size exclusion chromotography data of both the E. coli
and P. pastoris derived materials strongly encourage the
further research and characterization of these molecular
species. It should be noted that in analogy to the scFv
polypeptides, the formation of bispecific DiFabodies con-
taining two different sets of V regions seems easily achiev-
able using designs homologous to those described for
single chain Fvs.
Conclusion
The novel antibody design scFabΔC can be used for the
production of soluble antibody fragments in E. coli and
Pichia pastoris and is compatible with the phage display
technology. In particular, it allows the use of common
standard detection secondary sera, thus avoiding addi-
tional anti-tag antibody. Further, reagents with high
Size exclusion analysis of soluble antibody fragments pro- duced in P. pastoris Figure 9
Size exclusion analysis of soluble antibody fragments pro-
duced in P. pastoris. 500 μg purified antibody fragments of the 
scFabΔC format were separated on Superdex 200.
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apparent affinity can be created due to the avidity effects
of DiFabodies without any subcloning steps. This advan-
tage is of particular value for high throughput proteome
binder generation projects.
Methods
pHAL scFab phage display vectors
Standard cloning procedures were performed according to
Sambrook and Russell [39]. The pHAL vectors containing
the different antibody formats were derived from the
phagemid vector pHAL1 [9]. This vector allows both anti-
body phage display and expression of soluble antibody
fragments due to an amber stop codon between the anti-
body coding region and gIII.
Construction of pHAL1-D1.3scFv (Fig. 1) was done by
assembly PCR. VL fragment and VH fragment DNA were
amplified from pHAL1-D1.3Fab [9] and assembled by a
third PCR. The PCR product was cloned into the NheI and
NotI site of pHAL1. For the construction of pHAL1-
D1.3scFab, the coding region of the 34 amino acids gly-
cine-serine linker (Fig. 1b) was amplified from the M13
geneIII (gIII) of pHAL1-D1.3Fab, by assembly PCR. The
PCR product was cloned into the BssHII and PstI site of
Antigen binding ELISA of soluble antibody fragments produced in P. pastoris with 100 ng/well lysozyme or BSA coated per well Figure 10
Antigen binding ELISA of soluble antibody fragments produced in P. pastoris with 100 ng/well lysozyme or BSA coated per well. 
A serial dilution of gel filtration purified fractions of scFabΔC ranging from 8 ng/mL to 1 μg/mL were applied, the D1.3 antibody 
fragments were detected using Protein L HRP conjugate (1:10000). Measurements were done in duplicate.BMC Biotechnology 2007, 7:14 http://www.biomedcentral.com/1472-6750/7/14
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pHAL1-D1.3Fab. Two codons were deleted by PCR primer
directed mutagenesis for the construction of pHAL1-
D1.3scFab-2 and the PCR product was cloned into the
BssHII and PstI site of pHAL1-D1.3scFab. For the construc-
tion of pHAL1-D1.3scFab+2, two codons were added and
the PCR product was cloned into the BssHII and PstI site
as described. Both cysteines which connect both antibody
chains were deleted to construct pHAL1D1.3 C. The
cysteine of the LC was deleted by PCR primer directed
mutagenesis and assembled with by a second PCR in
which the cysteine of the Fd fragment was deleted. The
PCR-product was cloned into the BssHII and NotI site.
Transformations of XL1-Blue MRF' (Stratagene, Amster-
dam, Netherlands) with the constructs were done by elec-
troporation according to the manufacturers' instruction.
All steps in vector construction and antibody cloning were
confirmed by sequencing of the affected regions.
pOPE101 scFab production vectors
The D1.3scFv, D1.3Fab and D1.3scFabΔC DNA was were
cloned from the vectors pHAL1-D1.3scFv, pHAL1-
D1.3Fab and pHAL1-D1.3scFabΔC into the E. coli expres-
sion vector pOPE101-XP using the restriction sites EcoRI
and NotI. pOPE101-XP is a modification of pOPE101-
215yol [29] with the scFv coding sequence replaced by the
short DNA sequence containing stop codons in all three
reading frames. This vector contains a myc-tag and a his-
tag for detection and purification.
Illustration of scFabΔC and the multimerisation forms DiFabody and TriFabody Figure 11
Illustration of scFabΔC and the multimerisation forms DiFabody and TriFabody.BMC Biotechnology 2007, 7:14 http://www.biomedcentral.com/1472-6750/7/14
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pPICZ-α scFab vectors for the expression in P. pastoris
D1.3scFabΔC DNA was cloned from pOPE101-D1.3Fab
into the P. pastoris expression vector pPICZaA (Invitrogen,
Karlsruhe, Germany) using the restriction sites XbaI and
XhoI.
Antibody phage production
50 mL 2xTY medium [29] + 100 μg/mL ampicillin + 100
mM glucose were inoculated with an overnight culture to
O.D.600 = 0.1. Bacteria were grown to O.D.600 = 0.4 – 0.5
at 37°C and 250 rpm. 2 mL XL1-Blue MRF' (Stratagene)
(~1 × 109 bacteria) were infected with 2 × 1010 helper
phage M13K07 (Stratagene) or Hyperphage [26,27,31],
incubated at 37°C for 30 min without shaking, followed
by 30 min at 250 rpm. The infected cells were harvested
by centrifugation for 10 min at 3220 × g and the pellet was
resuspended in 30 mL 2xTY + 100 μg/mL ampicillin + 50
μg/mL kanamycin. Phage were produced at 30°C and 250
rpm for 16 h. Cells were pelleted for 10 min at 10000 × g.
Phage in the supernatant were precipitated with 1/5 vol-
ume of 20% PEG/2.5 M NaCl solution for 1 h on ice with
gentle shaking before being pelleted 1 h at 10000 × g at
4°C. The precipitated phage were resuspended in 10 mL
phage dilution buffer (10 mM TRIS, 20 mM NaCl, 2 mM
EDTA, the pH was adjusted to pH 7.5 with HCl), precipi-
tated again with 1/5 volume of PEG solution as given
above for 20 min on ice and pelleted 30 min at 10000 × g
at 4°C. The precipitated phage were resuspended in 300
μL phage dilution buffer and cell debris was pelleted by
additional centrifugation for 5 min at 15400 × g at 20°C.
The supernatant containing the antibody phage were
stored at 4°C. Phage titration (cfu/mL) was done accord-
ing to Koch et al. [40] with one modification: the infected
bacteria were pipetted directly onto LB agar plates, omit-
ting nitrocellulose sheets.
Production of soluble antibody fragments using the phage 
display vector pHAL1
Soluble antibody fragments were produced in shaking
flasks or microtiter plates (MTPs). For expression in shak-
ing flasks, 100 mL 2xTY medium + 100 μg/mL ampicillin
+ 100 mM glucose were inoculated 1:20 with an overnight
culture of XL1-Blue MRF' containing the appropriate vec-
tor and grown at 37°C and 250 rpm for 2 h. Bacteria were
harvested by centrifugation for 20 min at 3900 × g. The
pellet was resuspended in 100 mL 2xTY + 100 μg/ml Amp-
icillin + 20 μM IPTG at 30°C and 250 rpm overnight. 13
mL PBS (phosphate buffered saline [39]) containing 1%
Tween20 were added and incubated at 30°C and 350 rpm
for additional 3.5 h. Cells were separated from the anti-
body containing supernatant by centrifugation for 10 min
at 7000 × g. For expression in MTPs 200 μl 2xTY medium
+ 100 μg/mL ampicillin + 100 mM glucose was inoculated
with 10 μL overnight culture and grown at 37°C and 1400
rpm for 2 h. Bacteria were harvested by centrifugation for
10 min at 2500 × g. The pellet was resuspended in 200 μl
2xTY + 100 μg/mL Ampicillin + 20 μM IPTG at 30°C and
1400 rpm overnight. 50 μL PBS with 1% Tween20 were
added and incubated at 30°C and 1400 rpm for addi-
tional 3.5 h. Cells were separated from the antibody con-
taining supernatant by centrifugation for 10 min at 3200
× g.
Production of soluble antibody fragments using the vector 
pOPE101-XP
Various D1.3 antibody formats were produced in shaking
flasks according to Dübel et al. [41]. Briefly, 300 mL 2xTY
+ 100 μg/mL glucose + 100 μg/mL ampicillin were inocu-
lated with an overnight culture yield to O.D.600 < 0.1 and
cultured at 30°C and 250 rpm. The induction was started
by adjusting to 50 μM IPTG at O.D.600 = 0.6 and shaken
for 20 h. Bacteria were harvested by centrifugation for 10
min at 4400 × g at RT. Pellets were resuspended in 30 mL
ice cold PE buffer, pH 8 (500 mM sucrose, 100 mM Tris,
1 mM EDTA) and incubated for 20 min on ice, interrupted
by short vortexing every 5 min. Subsequently the bacteria
were pelleted for 30 min at 30000 × g at 4°C. The super-
natant (periplasmic fraction) was stored at -20°C. The
pellet was resuspended in 30 mL ice-cold dH2O and incu-
bated for 20 min on ice, interrupted by short vortexing
every 5 min. Spheroblasts were centrifuged for 30 min at
30000 × g and 4°C. The supernatant (osmotic shock prep-
aration) was stored at -20°C.
Production of scFab in P. pastoris
Transformation of P. pastoris (KM71) (Invitrogen, Karl-
sruhe, Germany) was done according to the manufactur-
ers recommendations. Positive clones were selected over
YPD-Zeocin (100 μg/mL). To further select transformed
clones for good antibody secretion a screening by 96 deep
well (Greiner, Flacht, Germany) expression was per-
formed using 500 μL BMGY medium, pH 6.0 [42] for 24
h at 30°C and 350 rpm. Protein synthesis was induced by
changing the media to 500 μL BMMY, pH 6.0 containing
1% MeOH [42] and further incubation for 48 hours.
Supernatant was harvested by centrifugation for 10 min,
1500 × g and analysed by antigen ELISA (using Protein L-
HRP for detection). Identified clones showing high anti-
body secretion were expressed in 2 L shake flask contain-
ing 500 mL BMGY media which was inoculated to an
OD600 0.5 and grown overnight. Protein production was
induced by exchanging the media after 24 h with BMMY
containing 1% MeOH and further incubation for 48 h,
before collecting the supernatent by centrifugation for 10
min and 1500 × g.
Protein L purification of soluble antibody fragments
Soluble antibody fractions from E. coli and  P. pastoris
expression were purified by affinity chromatography
using a Protein L column (Pierce, Bonn, Germany). AfterBMC Biotechnology 2007, 7:14 http://www.biomedcentral.com/1472-6750/7/14
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loading, the column was washed with 10 column vol-
umes PBS, pH 7.4. Antibody fragments were eluted with
glycine buffer 0.1 M, 0.15 M NaCl, pH 2.6 with immedi-
ate neutralization by TRIS/HCl buffer 1 M, pH 9.0. Frac-
tions were stored at -20°C.
Immobilized metal affinity chromatography (IMAC) 
purification of soluble antibody fragments
Soluble antibody fragments were purified from E. coli
derived material by affinity chromatography using IMAC.
Chromatography using 1 mL Chelating Sepharose Fast
Flow (Amersham Biosciences, Freiburg, Germany) was
done according to the manufacturers' instruction using 10
mM imidazol containing buffer (20 mM Na2 HPO4, 0.5
M NaCl, 10 mM imidazol) when loading the beads with
the protein solution, using 1× time 10 mM imidazol and
3× times 50 mM imidazol buffer for washing and PBS, pH
7.4 with 100 mM EDTA for the elution of the 6 × histidine
tagged proteins.
Antigen binding ELISA
Microtiter plates (Costar, Cambridge, USA) were coated
with 100 ng hen egg white lysozyme in 100 μL 0.1 M
NaHCO3, pH 9.6 per well over night at 4°C. Coated wells
were washed 3× with PBS and blocked with 2% (w/v)
skim milk powder in PBS for 1.5 h at RT, followed by 3×
washing with PBS. Antibody phage or soluble antibody
fragments were diluted in 100 μL blocking solution and
incubated for 1.5 h, followed by 5× washing with PBST
(PBS + 0.1% (v/v) Tween 20). Bound antibody phage
were detected with mAb anti-M13 conjugated with HRP
(Amersham Biosciences, Freiburg, Germany) (1:5000),
soluble antibody fragments were detected either with
mAb mouse anti-Strep-tag (Qiagen, Hilden, Germany)
(1:10000) and mAb goat anti-mouse conjugated with
HRP (1:50000), with mAb anti-myc tag (9E10 hybridom)
(1:25) and mAb goat anti-mouse conjugated with HRP
(1:50000) or with protein L conjugated with HRP (Pierce)
(1:10000) and visualised with TMB (3,3',5,5'-tetramethyl-
benzidine) substrate. The staining reaction was stopped
by adding 100 μL 1 N sulphuric acid. The absorbances at
450 nm and scattered light at 620 nm were measured and
the 620 nm reference was subtracted using a SUNRISE
microtiter plate reader (Tecan, Crailsheim, Germany).
SDS-PAGE and Immunoblot
Antibody phage or soluble antibody fragments were sepa-
rated by SDS-PAGE and blotted onto PVDF membrane.
The membrane was blocked with 2% (w/v) skim milk
powder in PBST for 1 h at RT. For the detection of anti-
body phage, the minor coat protein pIII was detected with
1:1000 diluted mouse mAb anti-pIII (Mobitec, Göttingen,
Germany) for 1.5 h at RT, followed by 2× washing with
PBST. Goat anti-mouse (Fc specific) (Sigma, Taufkirchen,
Germany) conjugated with AP 1:1000 diluted was used
for detection and visualised by NBT/BCIP. For the detec-
tion of soluble antibody fragments the mAb mouse anti-
myc (supernatant 9E10 1:25) was used as primary anti-
body and goat anti-mouse conjugated with AP (Sigma,
Taufkirchen, Germany) (1:2000) was used as secondary
antibody.
Gel filtration
Molecular sizes of purified scFabs were evaluated by size
exclusion chromatography on a calibrated Superdex 200
10/300 GL column (Amersham Bioscience) with PBS, pH
7.4, at a flow rate of 1 mL/min. Samples were fractionated
and stored for further ELISA analysis at 4°C.
Affinity determination
Affinity measurements were done using surface plasmon
resonance (SPR). The analysis was performed with a
Biacore2000 (Biacore, Sweden) using a CM5 chip. Lys-
ozyme and BSA were bound on flow cells via amine cou-
pling. The flow rate was 30 μl/min at 25°C using HEPES
buffer [39]. Sample concentration of D1.3 antibody vari-
ants loaded on flow cells ranged from 6 × 10-8 to 5 × 10-9
M. The curve fitting was performed and the kinetics were
analyzed using the Biacore software package.
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